Research
Hormonal
The guidelines focus on cardiovascular risk stratification and management of cardiovascular risk factors in diabetes.
Focus on cardiovascular risk factors is essential for diabetes management.
StrongSupportsmedium confidence
This guideline explores the management of diabetes with a focus on cardiovascular risk stratification, lifestyle and pharmacological management of cardiovascular risk factors.
Why this rating
Based on the guidelines derived from meta-analyses and clinical trials.
Source
Beyond boundaries: exploring the latest guidelines for diabetes and cardiovascular health
Victora Ruszala et al. · British Journal of Cardiac Nursing · 2024
DOI 10.12968/bjca.2024.0020
Meta-analysis
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →